CLAIMS

1. A method of treating hidradenitis suppurativa patient and/or atopic dermatitis in a patient having an elevated level of an inflammatory biomarker, comprising administering to the patient a therapeutically effective amount of an IRAK4 degrader.

2. A method of treating hidradenitis suppurativa patient and/or atopic dermatitis in a patient, comprising selecting a patient having an elevated level of an inflammatory biomarker, and administering to the patient a therapeutically effective amount of an IRAK4 degrader.

3. A method of treating hidradenitis suppurativa patient and/or atopic dermatitis in a patient, comprising measuring an inflammatory biomarker level in a sample of a patient, selecting a patient having an elevated level of an inflammatory biomarker, and administering to the patient a therapeutically effective amount of an IRAK4 degrader.

4. A method of treating hidradenitis suppurativa patient and/or atopic dermatitis in a patient having a reduced level of an inflammatory biomarker after a treatment with an IRAK4 degrader, comprising administering to the patient a therapeutically effective amount of an IRAK4 degrader.

5. A method of treating hidradenitis suppurativa patient and/or atopic dermatitis in a patient, comprising selecting a patient having a reduced level of an inflammatory biomarker after a treatment with an IRAK4 degrader, and administering to the patient a therapeutically effective amount of an IRAK4 degrader.

6. A method of treating hidradenitis suppurativa patient and/or atopic dermatitis in a patient, comprising measuring an inflammatory biomarker level in a sample of a patient after a treatment with an IRAK4 degrader, selecting a patient having a reduced level of an inflammatory biomarker after a treatment with an IRAK4 degrader, and administering to the patient a therapeutically effective amount of an IRAK4 degrader.

7. A method of treating hidradenitis suppurativa patient and/or atopic dermatitis in a patient, comprising administering to a patient a therapeutically effective amount of an IRAK4 degrader, measuring an inflammatory biomarker level in a sample of a patient after a treatment with an IRAK4 degrader, selecting a patient having a reduced level of an inflammatory biomarker after a treatment with an IRAK4 degrader, and administering to the patient a therapeutically effective amount of an IRAK4 degrader.

8. The method of any one of claims 3, 6, and 7, wherein the sample is a blood sample or a skin sample.

9. The method of any one of claims 1-8, wherein the inflammatory biomarker is IRAK4 in circulating peripheral blood mononuclear cells (PBMC).

10. The method of claim 9, wherein the circulating PBMC is selected from B cells, CD4–/CD8– (double-negative, DN) T cells, CD4+ T cells, CD8+ T cells, monocytes, and NK cells.

11. The method of any one of claims 1-8, wherein the inflammatory biomarker is a chemokine selected from CCL2, CCL20, CSF3, CXCL1, CXCL2, CXCL6, CXCL8, CXCL11, and CXCL13.

12. The method of any one of claims 1-8, wherein the inflammatory biomarker is selected from GZMB and PRF1.

13. The method of any one of claims 1-8, wherein the inflammatory biomarker is a cytokine selected from IFNG, IL10, IL1B, IL32, IL36G, IL6, IRF7, SOCS3, and TNF.

14. The method of any one of claims 1-8, wherein the inflammatory biomarker is a cytokine receptor selected from IL2RA, IL2RB, and IL18RAP.

15. The method of any one of claims 1-8, wherein the inflammatory biomarker is selected from MYD88, TLR1, TLR2, TLR3, TLR4, TLR6, TLR8, and TLR9.


16. The method of any one of claims 1-8, wherein the inflammatory biomarker is selected from NLRP3 and PTGS2.

17. The method of any one of claims 1-8, wherein the inflammatory biomarker is selected from CXCL6, CXCL8, CXCL1, CGAS, SOCS3, CXCL13, and CTSL.


18. The method of any one of claims 1-3, wherein the elevated level of the inflammatory biomarker refers to that the amount or concentration of the inflammatory biomarker in the patient is about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to the amount or concentration of the inflammatory biomarker in a healthy person.

18. The method of any one of claims 4-7, wherein the reduced level of the inflammatory biomarker refers to that the amount or concentration of the inflammatory biomarker in the patient is reduced by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%, after a treatment with an IRAK4 degrader.

19. The method of any one of claims 1-18, wherein the IRAK4 degrader is Degrader 1:



, or a pharmaceutically acceptable salt thereof, or Degrader 2:



, or a pharmaceutically acceptable salt thereof.